NEC’s AI Supports Doctors to Detect Neoplasia in Barrett’s Esophagus During Endoscopic Procedures
28.5.2021 11:00:00 EEST | Business Wire | Press release
NEC Corporation (NEC; TOKYO: 6701) today announced the development of an AI technology for supporting doctors to detect neoplasia in Barrett’s esophagus during endoscopic procedures. This is the world's first technology of its kind to comply with the requirements for CE mark labeling, a European safety, health and environmental protection standard (*1), and is being released as WISE VISION® Endoscopy, where it will soon be available in Europe to help doctors in the detection of Barrett’s neoplasia (*2).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210528005090/en/
Provided by Professor Pradeep Bhandari: “Once the neoplasia is found, the system takes a still image and transfers it to the top right corner of a screen as a reference image for endoscopists. It also has a heat map which shows the area of the AI-predicted neoplasia.” (Graphic: Business Wire)
This software is connected to endoscopy processors and automatically notifies users of potential Barrett’s neoplasia from images captured during endoscopic procedures.
Barrett’s esophagus is a pre-cancerous condition in which the inner lining of the esophagus is replaced by a lining that resembles that of the stomach. Patients with Barrett’s esophagus have 30-40 fold higher risk of developing cancer of the esophagus as compared to the normal population (*3).
However, if this cancer can be detected at an early stage, then it can be removed through the endoscope and a patient can be cured.
To help resolve this issue, NEC collaborated with Professor Pradeep Bhandari (Portsmouth, UK), Chair of the European Society of Gastrointestinal Endoscopy (ESGE) Research Committee, in development of this new technology to support doctors to detect Barrett’s neoplasia during examination. In developing this solution, NEC applied its face recognition technology that has been highly evaluated (*4) by the National Institute of Standards and Technology (NIST) in the United States, and belongs to NEC’s portfolio of cutting-edge AI technologies, “NEC the WISE.”
“I am delighted that NEC, as one of the world’s leaders in AI technology, has entered the field of endoscopy and developed WISE VISION® Endoscopy to detect and help manage Gastrointestinal neoplasia,” said Professor Pradeep Bhandari, Chair of the ESGE Research Committee.
For More Information
URL: https://www.nec.com/en/press/202105/global_20210528_01.html
Notes:
(*1) Source: NEC Corporation
(*2) "WISE VISION" is a registered trademark of NEC Corporation in the United States of America, the European Union and the United Kingdom.
(*3) Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med. 2009 Dec 24;361(26):2548-56. doi: 10.1056/NEJMcp0902173. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450. PMID: 20032324.
(*4) NEC Face Recognition Technology Ranks First in NIST Accuracy Testing
https://www.nec.com/en/press/201910/global_20191003_01.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210528005090/en/
Contact information
Joseph Jasper
j-jasper(at)nec.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 09:00:00 EEST | Press release
Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidates that demonstrated real, measurable activity against tumors. This collaboration marks an important milestone for Okomera, which is signing its first commercial agreement with an international pharmaceutical group. Under the terms of the agreement, Servier will operate Okomera’s platform fully independently. Its teams will be able to ge
Bureau Veritas: Double Digit Total Revenue Growth in the Third Quarter of 202621.10.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): The execution of LEAP | 28 has transformed Bureau Veritas into a more focused, faster-growing and higher-performing multi-specialist company. Its Product Line-centric operating model combines the Company’s global scale and resilience with clear priorities, stronger accountability and deep specialist expertise. This creates a more repeatable growth model, enabling faster execution, stronger capabilities and higher conversion of growth into profitability. Q3 2026 Key figures1 › New reporting structure effective July 1st, 2026, comprising four divisions: Industrials & Commodities, Buildings & Infrastructure, Business Assurance, and Product Testing & Services, excluding the planned for exit businesses of Oil & Petrochemicals and Coal Testing and Inspection, and “Government Services”; › Revenue of EUR 1,569.7 million, up 10.1% year-on-year and up 6.2% organically; • Positive scope effect of 1.8%, from accelerated bolt-on acquisitions (+2.7% contribution), net of
AI Emerges as CEOs' Most Critical Challenge, Egon Zehnder Study Finds21.10.2026 08:00:00 EEST | Press release
Artificial intelligence has emerged as the most critical challenge facing CEOs worldwide, ahead of geopolitical instability and economic uncertainty, according to The CEO Response, Egon Zehnder's third annual study of 843 global chief executives. Nearly half of CEOs (48%) consider the adoption and impact of AI an extremely critical challenge, up from 37% in 2025. Geopolitical instability (44%) and economic uncertainty (40%) follow, while 62% expect geopolitical disruption to increase over the next 12 months. These challenges are shaping where CEOs are focusing their efforts. Half (50%) identify AI investment among the three most important changes they're making to their organizations, followed by innovation (48%) and improving their cost base (41%). By comparison, 29% selected upskilling and talent development as a top priority. “CEOs can invest in AI much faster than they can change how an organization works,” said Francesco Buquicchio, Global CEO of Egon Zehnder. “That gap matters. L
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership21.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from October 21-23, 2026. The company will present eight scientific abstracts, alongside a symposium and six Meet-the-Expert sessions, all highlighting the expanding benefits of Relfydess, Sculptra, and the Restylane range.1-8 Together, the data demonstrate Galderma’s commitment to meeting the evolving needs of patients and healthcare professionals through innovation that addresses growing needs, from menopause-related skin changes and regenerative aesthetic solutions, to body indications. Data across face and body indications showcase the power of Sculptra and Restylane Data on Sculptra, the first proven regenerative biostimulator, will be shared at AMWC Dubai, following its approval in the UAE expanding its current clinical application for the face to include key body areas:
Sihoo esittelee uuden sukupolven ergonomisia toimistoratkaisuja ORGATEC 2026 -messuilla20.10.2026 21:14:00 EEST | Tiedote
ORGATEC 2026 -messujen lähestyessä ergonomisten istuinratkaisujen asiantuntija Sihoo esittelee uuden sukupolven työympäristöratkaisujaan hallissa 8.1, osastoilla A-060 ja B-061. Messujen teeman ”Tiloista vuorovaikutukseen: tilojen suunnittelu jatkuvasti muuttuvassa maailmassa” mukaisesti Sihoo esittelee, kuinka mukautuva ergonominen suunnittelu tukee asentojen vaihtelua ja nykyaikaisten työympäristöjen muuttuvia tarpeita. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20261020772047/fi/ Sihoo ORGATEC 2026 -messuilla Kölnissä Käyttötilanteisiin perustuva elämyksellinen tila Avoimeen tilakonseptiin perustuvalla Sihoon osastolla yhdistyvät oranssin ja valkoisen värimaailma, kerrokselliset kattorakenteet, läpikuultavat väliseinät ja integroitu valaistus. Korkeussäädettävillä työpöydillä ja näytöillä varustetut työpisteet sekä yhteistyöhön suunnitellut istuma-alueet jäljittelevät tuttuja toimistoympäristöjä ja havainnollistavat,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
